Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (2288)	12/13/2000 12:06:29 AM
From: Scott H. Davis	Read Replies (2) \| Respond to of 52153

Surpreme Ct. effectively rules against Gore, the Democratic Committee chair calle on Gore to conceed - will there be a "sigh of relief" rally or is it mostly priced in already? Thoughts? Scott FYI MRK expressed confidence with their HIV vaccine dailynews.yahoo.com MRK licensed VICL naked DNA technology for this (VICL went up 6% without a press release) by which enough common DNA can be presented in a way that does not transmit the whole DNA yet is enough to provoke an immune system response. Previously this thread assessed ways to value biotechs. Question I would like to pose is how does one add subject valuation of management effectiveness to a valuation? VICL, at least in the 4 years I have followed has not had any bad news - no programs cancelled or cut back, not partnet problems, no partnerships cancelled, low cash burn rate. Taken together thier burn rate is low since they don't waste money on programs that don't work. No FDA problems. No shareholder lawsuits. Lower than average dilution. Unfortunately low analyst coverage and a price where it was 4 1/2 years ago despite significant progress & lots of cash. How do you subjectively factor pretty consistant lack of market response? (this years winter/spring biotech binge being the glaring exception.) Thoughts on these?